当前位置:
X-MOL 学术
›
Inflammopharmacology
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Metformin ameliorates animal models of dermatitis.
Inflammopharmacology ( IF 5.8 ) Pub Date : 2020-04-28 , DOI: 10.1007/s10787-020-00704-8 Soo Young Choi 1 , Chanmi Lee 1 , Min-Jeong Heo 1 , Yeong Min Choi 1 , In-Sook An 1 , Seunghee Bae 2 , Sungkwan An 2 , Jin Hyuk Jung 1
Inflammopharmacology ( IF 5.8 ) Pub Date : 2020-04-28 , DOI: 10.1007/s10787-020-00704-8 Soo Young Choi 1 , Chanmi Lee 1 , Min-Jeong Heo 1 , Yeong Min Choi 1 , In-Sook An 1 , Seunghee Bae 2 , Sungkwan An 2 , Jin Hyuk Jung 1
Affiliation
Metformin, a potent AMPK activator is the most commonly used drug for diabetes. According to recent reports, metformin lowers the risk of diabetic complications and inflammatory diseases. We found the expression levels of AMPK subunits including PRKAA1, PRKAA2, PRKAB1 and PRKAB2 are decreased in skin biopsies of dermatitis patients from multiple datasets. Interestingly, metformin treatment ameliorates dermatitis symptom in animal model of dermatitis using O-tetradecanoylphorbol-13-acetate (TPA). Especially, the levels of epidermis and dermis thickness were decreased by metformin. We found NFκB activity as well as of gene expression associated with collagen synthesis are attenuated by metformin treatment. These results suggest that metformin treatment alleviates animal model of dermatitis.
中文翻译:
二甲双胍改善了皮炎的动物模型。
二甲双胍是一种有效的AMPK激活剂,是最常用的糖尿病药物。根据最近的报道,二甲双胍可降低糖尿病并发症和炎症性疾病的风险。我们发现从多个数据集来看,皮炎患者的皮肤活检中包括PRKAA1,PRKAA2,PRKAB1和PRKAB2的AMPK亚基的表达水平降低。有趣的是,二甲双胍治疗可使用O-十四烷酰佛波醇13-乙酸盐(TPA)改善皮炎动物模型中的皮炎症状。特别是二甲双胍可降低表皮和真皮层的水平。我们发现二甲双胍治疗减弱了NFκB活性以及与胶原合成相关的基因表达。这些结果表明二甲双胍治疗减轻了皮炎的动物模型。
更新日期:2020-04-28
中文翻译:
二甲双胍改善了皮炎的动物模型。
二甲双胍是一种有效的AMPK激活剂,是最常用的糖尿病药物。根据最近的报道,二甲双胍可降低糖尿病并发症和炎症性疾病的风险。我们发现从多个数据集来看,皮炎患者的皮肤活检中包括PRKAA1,PRKAA2,PRKAB1和PRKAB2的AMPK亚基的表达水平降低。有趣的是,二甲双胍治疗可使用O-十四烷酰佛波醇13-乙酸盐(TPA)改善皮炎动物模型中的皮炎症状。特别是二甲双胍可降低表皮和真皮层的水平。我们发现二甲双胍治疗减弱了NFκB活性以及与胶原合成相关的基因表达。这些结果表明二甲双胍治疗减轻了皮炎的动物模型。